{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:41:43Z","timestamp":1790361703832,"version":"4.1.0"},"reference-count":72,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Despite progress in the upfront treatment of diffuse large B cell lymphoma (<jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>), patients still experience relapses. Salvage chemotherapy followed by autologous stem cell transplantation (<jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>) is the standard second\u2010line treatment for relapsed and refractory (R\/R) <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>. However, half of the patients will not be eligible for transplantation due to ineffective salvage treatment, and the other half will relapse after <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>. In randomized studies, no salvage chemotherapy regimen is superior to another. The outcomes are affected by the secondary International Prognostic Index at relapse and various biological factors. The strategy is less clear in patients who require third\u2010line treatment. A multicohort retro<jats:styled-content>s<\/jats:styled-content>pe<jats:styled-content>c<\/jats:styled-content>tive non\u2010Hodgkin lymphoma research (<jats:styled-content style=\"fixed-case\">SCHOLAR<\/jats:styled-content>\u20101) study conducted in 636 patients with refractory <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content> showed an objective response rate of 26% (complete response 7%) to the next line of therapy with a median overall survival of 6\u00b73\u00a0months. In the case of a response followed by transplantation, long\u2010term survival can be achieved in <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content> patients. There is clearly a need for new drugs that improve salvage efficacy. Encouraging results have been reported with chimeric antigen receptor \u2010T cell engineering, warranting further studies in a well\u2010defined control group of refractory patients. The Collaborative Trial in Relapsed Aggressive Lymphoma (<jats:styled-content style=\"fixed-case\">CORAL<\/jats:styled-content>) was used as a handy framework to build the discussion.<\/jats:p>","DOI":"10.1111\/bjh.15412","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T10:23:53Z","timestamp":1527589433000},"page":"633-643","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":165,"title":["How I manage patients with relapsed\/refractory diffuse large B cell lymphoma"],"prefix":"10.1111","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-3589","authenticated-orcid":false,"given":"Christian","family":"Gisselbrecht","sequence":"first","affiliation":[{"name":"H\u00f4pital Saint Louis Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Den Neste","sequence":"additional","affiliation":[{"name":"Cliniques universitaires UCL Saint\u2010Luc Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1704610"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000182405.65041.8b"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651968"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.02.005"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.016"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9593"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-406033"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-199679"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22911"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.10.005"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236471"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506048"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-S2-41"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.9416"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.06.036"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26135"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.11.023"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.408"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.0198"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30145-1"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001653736"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13273"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy056"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.2596"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144550"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000801)89:3<647::AID-CNCR21>3.0.CO;2-R"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2012.01.006"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-622084"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.055"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13440"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1704767"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9585"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090597"},{"key":"e_1_2_15_43_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.032"},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_15_45_1","article-title":"A comparison of one year outcomes in ZUMA\u20101 (axicabtagene ciloleucel) and SCHOLAR\u20101 in patients with refractory, aggressive non\u2010Hodgkin lymphoma (NHL)","volume":"130","author":"Neelapu S.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.172882"},{"key":"e_1_2_15_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70128-2"},{"key":"e_1_2_15_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70212-7"},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_15_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.027"},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606939"},{"key":"e_1_2_15_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802561"},{"key":"e_1_2_15_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"e_1_2_15_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577189"},{"key":"e_1_2_15_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.273"},{"key":"e_1_2_15_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.2813"},{"key":"e_1_2_15_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2004"},{"key":"e_1_2_15_58_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.060434"},{"key":"e_1_2_15_59_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0499"},{"key":"e_1_2_15_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_15_61_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0054"},{"key":"e_1_2_15_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5957"},{"key":"e_1_2_15_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.4423"},{"key":"e_1_2_15_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.213"},{"key":"e_1_2_15_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108415"},{"key":"e_1_2_15_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651380"},{"key":"e_1_2_15_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9453"},{"key":"e_1_2_15_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf189"},{"key":"e_1_2_15_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884"},{"key":"e_1_2_15_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.226"},{"key":"e_1_2_15_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24824"},{"key":"e_1_2_15_72_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.964702"},{"key":"e_1_2_15_73_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.147256"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T06:43:53Z","timestamp":1694760233000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/bjh.15412"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15412","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"2018-05-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}